stockrow
Friday 6 November 2026
Export ABVX’s income statement to Excel — free account
Abivax SA Sponsored ADR
ABVX Healthcare Biotechnology
- EPS
- −98.8%
- Free cash flow
- −48.3%
- Total debt
- −98.5%
Quarter to June 2026, against a year earlier
86.10
1.92
+2.28%
Follow ABVX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 4 | 80 | 375 | +818.4% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (23) | (39) | (46) | (54) | (64) | (160) | (191) | (374) | (464) | +48.8% | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | — | (19) | (34) | (43) | (49) | (64) | (160) | (191) | (380) | (459) | +53.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (1.83) | (2.81) | (2.99) | (2.92) | (3.35) | (3.71) | (3.03) | (5.46) | (6.06) | +16.9% | ||||||
| Cash flow | — | — | (1.69) | (2.52) | (2.38) | (3.22) | (2.98) | (2.44) | (2.64) | (2.62) | (2.84) | +6.4% | ||||||
| Capex | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (0.02) | (0.01) | (0.01) | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | — | — | (1.69) | (2.52) | (2.38) | (3.22) | (2.99) | (2.45) | (2.66) | (2.62) | (2.84) | +6.5% | ||||||
| Book value | — | — | 3.23 | 1.09 | 0.40 | 1.95 | 0.40 | 4.93 | 0.70 | 7.41 | 5.35 | +12.6% | ||||||
| Shares, m | — | — | 10 | 12 | 14 | 17 | 19 | 43 | 63 | 70 | 75 | +31.6% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (17) | (31) | (34) | (54) | (57) | (105) | (167) | (182) | (226) | +40.1% | |||||
| Capex | — | — | (1) | (1) | (1) | (2) | 0 | 0 | (1) | 0 | 0 | (21.8%) | ||||||
| Free cash flow | — | — | (17) | (31) | (34) | (54) | (57) | (105) | (167) | (182) | (226) | +40.1% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 13 | 2 | 14 | 49 | 4 | 234 | 83 | 552 | 414 | +70.7% | |||||
| Net debt | — | — | (2) | 12 | 6 | (8) | 13 | (223) | (60) | (607) | (476) | +120.4% | ||||||
| Shareholders’ equity | — | — | 33 | 13 | 6 | 33 | 8 | 212 | 44 | 515 | 426 | +48.2% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | 0.00 | (57.22) | (58.92) | (45.95) | (62.40) | (73.76) | (66.21) | (86.11) | (137.67) | (86.1) pt | |||||
| ROIC | — | — | 0.00 | 0.00 | 0.00 | 0.00 | (208.88) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | — | — | 0.00 | (148.81) | (451.99) | (254.34) | (317.63) | (145.55) | (148.96) | (136.07) | (249.78) | (136.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | — | — | 34 | 136 | 69 | 69 | — | +26.6% | |||||
| Revenue/emp, $m | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fundamentals updated 26 Oct 2026
Abivax SA Sponsored ADR vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| SYRE Spyre Therapeutics, Inc. | $9.2B | — (loss-making) | — (loss-making) | −100.00% (below 0%: shrinking) | n/m | −108.79% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ARWR Arrowhead Pharmaceuticals, Inc. | $8.1B | — (loss-making) | — (loss-making) | +171.02% (above 0%: growing) | n/m | −15.43% (below 0%: shrinking) | 100.00% | (226.03%) | Compare |
| CORT Corcept Therapeutics Incorporated | $7.8B | 47.5× | 39.8× | +63.97% (above 0%: growing) | +525.79% (above 0%: growing) | +160.98% (above 0%: growing) | 98.65% | 33.70% | Compare |
| CYTK Cytokinetics, Incorporated | $7.7B | — (loss-making) | — (loss-making) | +2,356.46% (above 0%: growing) | n/m | −6.73% (below 0%: shrinking) | 0.00% | (351.34%) | Compare |
| ABVX Abivax SA Sponsored ADR | $7.4B | — (loss-making) | — | — | n/m | −48.28% (below 0%: shrinking) | 0.00% | 0.00% | |
| PRAX Praxis Precision Medicines, Inc. | $7.3B | — (loss-making) | — (loss-making) | +1,349.13% (above 0%: growing) | n/m | −43.54% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| RYTM Rhythm Pharmaceuticals, Inc. | $7.3B | — (loss-making) | — (loss-making) | +79.59% (above 0%: growing) | n/m | +95.40% (above 0%: growing) | 86.79% | (42.63%) | Compare |
| AXSM Axsome Therapeutics, Inc. | $6.8B | — (loss-making) | — (loss-making) | +51.87% (above 0%: growing) | n/m | −1,078.34% (below 0%: shrinking) | 93.14% | (4.26%) | Compare |
| ORKA Oruka Therapeutics, Inc. | $6.4B | — (loss-making) | — | — | n/m | −43.00% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| Median of peers | $7.5B | — | — | +79.59% | — | −29.21% | 89.97% | (2.13%) |